Human papillomavirus type 16/18 up-regulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4705-4712

  Cheng, Ya Wen ^a   Lee, Huei ^b   Shiau, Ming Yuh ^c   Wu, Tzu Chin ^a,d   Huang, Tsung Teng ^a   Chang, Yih Hsin ^b  

^a Institutes of Medicine

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c Hung Kuang University

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2;

AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; VIRUS INFECTION; WESTERN BLOTTING; ADULT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 51049086171     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4675     Document Type: Article

References (29)

1. Chen CJ, Wu HY, Chuang YC, et al. Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. Anticancer Res 1990;10:971-6.
2. Lee CH, Ko YC, Goggins W, et al. Lifetime environmental exposure to tobacco smoke and primary lung cancer of nonsmoking Taiwanese women. Int J Epidemiol 2000;29:224-31.
3. Pisani P, Parkin MP, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
4. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999;111:581-7.
5. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001;82:49-56.
6. Malejczyk J, Malejczyk M, Urbanski A, et al. Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cell Immunol 1991;136:155-64.
7. Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene 2001;20:5799-809.
8. Syrjanen KJ. HPV infections and lung cancer. J Clin Pathol 2002;55:885-91.
9. Cheng YW, Chiou HL, Sheu GT et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-803.
10. Cheng YW, Wu MF, Wang J, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 2007; 67:10686-93.
11. DeVita F, Orditura M, Auriemma A, et al. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 1998;17:413-7.
12. Wojciechowska-Lacka A, Matecka-Nowak M, Adamiak E, et al. Serum level of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996;43:155-8.
13. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-6.
14. Soini Y, Nuorva K, Kamel D, et al. Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma. Thorax 1996;51:887-93.
15. Jiang M and Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8.
16. Yoshinouchi M, Yamada T, Kizaki M, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther 2003;8:762-8.
17. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
18. Puthier D, Bataille R, Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945-50.
19. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159: 2212-21.
20. Kuo ML, Chuang SE, Lin MT, Yang SY. The involvement of PI3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001;20:677-85.
21. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 1998;95:3644-9.
22. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylmositol-3 kinase. which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000;42:1-7.
23. Jee SH. Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001;20: 198-208
24. Tartour E, Gey A, Sastre-Garau X. et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 1994;54:6243-8
25. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirusimmortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol 1995;146:944-52.
26. Bihl M, Tamm M, Nauck M, et al. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 1998;19 606-12.
27. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. lmerleukm-6- dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 familyindependent survival pathway closely associated with Stat3 activation. Blood 2004;103:242-51.
28. Borner MM, Brousset P, Pfanner-Meyer B, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer1999;79:952-8.
29. Song L, Turkson J, Karras JG, Jove R, Haura B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65